668 results on '"De Preter, Katleen"'
Search Results
2. Defining the optimal setting for transcriptomic analyses on blood samples for response prediction in immunotherapy-treated NSCLC patients
3. Diagnosis of pediatric central nervous system tumors using methylation profiling of cfDNA from cerebrospinal fluid
4. Evaluation of single-sample network inference methods for precision oncology
5. Somatic Genomic Alterations in Neuroblastoma
6. NBAtlas: A harmonized single-cell transcriptomic reference atlas of human neuroblastoma tumors
7. A Fast, Affordable, and Minimally Invasive Diagnostic Test for Cancer of Unknown Primary Using DNA Methylation Profiling
8. SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry
9. Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma
10. miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma
11. Comprehensive RNA dataset of tissue and plasma from patients with esophageal cancer or precursor lesions
12. Digital PCR-based evaluation of nucleic acid extraction kit performance for the co-purification of cell-free DNA and RNA
13. When DNA gets in the way : A cautionary note for DNA contamination in extracellular RNA-seq studies
14. The RNA Atlas expands the catalog of human non-coding RNAs
15. Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma
16. MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression
17. ALK positively regulates MYCN activity through repression of HBP1 expression
18. Mapping the genomic landscape of inherited retinal disease genes prioritizes genes prone to coding and noncoding copy-number variations
19. miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma
20. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma
21. Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma.
22. Author Correction: Benchmarking of cell type deconvolution pipelines for transcriptomics data
23. Benchmarking of cell type deconvolution pipelines for transcriptomics data
24. Distinct Notch1 and BCL11B requirements mediate human γδ/αβ T cell development
25. Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring
26. Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer
27. Publisher Correction: The RNA Atlas expands the catalog of human non-coding RNAs
28. Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis
29. Asthma inflammatory phenotypes show differential microRNA expression in sputum
30. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
31. Author Correction: Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes
32. Publisher Correction: In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
33. Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes
34. Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma
35. Table S1 from Cross-Cohort Analysis Identifies a TEAD4–MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma
36. Data from Cross-Cohort Analysis Identifies a TEAD4–MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma
37. Supplementary Data from Cross-Cohort Analysis Identifies a TEAD4–MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma
38. Supplementary Table S1 from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
39. Figure S1-S6 from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
40. Supplementary Table 2 from Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature
41. MYCN targets OTX015_BRD4 and gene expression from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
42. Figure S2 from LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis
43. Supplementary Figure 2. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
44. Data from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
45. Supplementary Data from The Quassinoid Derivative NBT-272 Targets Both the AKT and ERK Signaling Pathways in Embryonal Tumors
46. Supplementary Figure 1, Tables 1-3 from miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples
47. Supplementary Table 1 from Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
48. Supplemental Data 10 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
49. supplemental figures from Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients
50. Supplemental Data 5 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.